Biotech Values

[RockRat]

Thanks for the dig. I've been waiting to see data on the clinical experience of patients taking these Copaxone knock offs that we all knew would be inadequate. Not sure why it took so long. In spite of Teva's continued position that clinical trials should be required of Copaxone generics, the presentation seems to provide some analytical techniques that would do the job of proving sufficient similarity. One of these is even lifted from a fairly old (2008) Momenta patent.

The slides do document how high that hurdle is, and may be the reason behind MNTA shares' underperformance in recent days.

Regards, RockRat